Article
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.
The lancet. HIV - 1 Dec 2017
Wijting Ingeborg, Rokx Casper, Boucher Charles, van Kampen Jeroen, Pas Suzan, de Vries-Sluijs Theodora, Schurink Carolina, Bax Hannelore, Derksen Maarten, Andrinopoulou Eleni-Rosalina, van der Ende Marchina, van Gorp Eric, Nouwen Jan, Verbon Annelies, Bierman Wouter, Rijnders Bart
Abstract excerpt
BACKGROUND: The high genetic barrier to resistance of dolutegravir might allow for its use as maintenance monotherapy in patients with HIV. We investigated whether dolutegravir monotherapy was non-inferior to combination antiretroviral therapy (ART) for maintaining virological suppression in patients with HIV-1 infection successfully treated with combination ART. METHODS: We did this open-label, phase 2,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.